Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 05, 2025 08:47 ET | Source: Tenax Therapeutics, Inc.

Tenax Therapeutics Announces $25 Million Private Placement

CHAPEL HILL, N.C., March 05, 2025 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX) (the “Company” or “Tenax Therapeutics”), a Phase 3, development-stage pharmaceutical company using...
March 05, 2025 08:42 ET | Source: Tenax Therapeutics, Inc.

Tenax Therapeutics Expands Phase 3 LEVEL Program, Advancing Two TNX-103 (Oral Levosimendan) Registrational Studies for the Treatment of PH-HFpEF

Amendment to Enlarge Phase 3 LEVEL Study, Increasing Statistical Powering, Accepted by FDA, Expected to be Fully Enrolled Around Year End 2025 Agreement by FDA to Initiate Second Global Phase 3...
March 03, 2025 08:00 ET | Source: Tenax Therapeutics, Inc.

Tenax Therapeutics to Participate in the Leerink Partners 2025 Global Healthcare Conference

CHAPEL HILL, N.C., March 03, 2025 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX) (“Tenax Therapeutics” or the “Company”), a Phase 3, development-stage pharmaceutical company focused on...
June 28, 2012 13:30 ET | Source: Tenax Therapeutics, Inc.

Oxygen Biotherapeutics Sets Year-End Financial Results Conference Call and Webcast for July 25th and General Annual Meeting for August 31st

MORRISVILLE, N.C., June 28, 2012 (GLOBE NEWSWIRE) -- Oxygen Biotherapeutics, Inc. (Nasdaq:OXBT) today announced that it plans to report fiscal-year 2012 financial results on Form 10-K on Tuesday, July...
June 15, 2012 08:05 ET | Source: Tenax Therapeutics, Inc.

Oxygen Biotherapeutics Announces Expected Closing on Second Installment of December 2011 Financing and Amends Agreement to Allow for a Third Tranche Later This Year Pending Shareholder Approval

MORRISVILLE, N.C., June 15, 2012 (GLOBE NEWSWIRE) -- Oxygen Biotherapeutics, Inc. (Nasdaq:OXBT) today announced that it has entered into definitive agreements with institutional investors to amend the...
May 31, 2012 09:38 ET | Source: Tenax Therapeutics, Inc.

Oxygen Biotherapeutics Study Reveals Dermacyte(R) Concentrate's Potential to Relieve Histamine-Induced Pruritus in Healthy Patients

MORRISVILLE, N.C., May 31, 2012 (GLOBE NEWSWIRE) -- Oxygen Biotherapeutics, Inc. (Nasdaq:OXBT) announced today that data from its clinical study to determine the efficacy of Dermacyte® in...
May 03, 2012 10:47 ET | Source: Tenax Therapeutics, Inc.

Oxygen Biotherapeutics Secures Long-Term Clinical Supply of Oxycyte(R)

MORRISVILLE, N.C., May 3, 2012 (GLOBE NEWSWIRE) -- Oxygen Biotherapeutics, Inc. (Nasdaq:OXBT), a development stage biomedical company ("the Company") focused on developing perfluorocarbon-based...
March 15, 2012 22:21 ET | Source: Tenax Therapeutics, Inc.

Oxygen Biotherapeutics Reports Financial Results for the Third Quarter FY2012

MORRISVILLE, N.C., March 15, 2012 (GLOBE NEWSWIRE) -- Oxygen Biotherapeutics, Inc. (Nasdaq:OXBT), a development stage biomedical company focused on developing oxygen-rich intravenous and topical...
March 01, 2012 16:44 ET | Source: Tenax Therapeutics, Inc.

Oxygen Biotherapeutics Announces Plan to Regionalize Its Sales & Marketing Efforts for Its Dermacyte(R) Oxygenating Skin Care Product Line

MORRISVILLE, N.C., March 1, 2012 (GLOBE NEWSWIRE) -- Oxygen Biotherapeutics, Inc. (Nasdaq:OXBT) today announced that the Company has modified its sales and marketing effort to focus on the regional...
February 01, 2012 07:30 ET | Source: Tenax Therapeutics, Inc.

Oxygen Biotherapeutics and Aurum Biosciences Enter Joint Research Agreement to Develop an Oxycyte(R)-Based Diagnostic Tool and Therapeutic for Acute Ischemic Stroke

MORRISVILLE, N.C., Feb. 1, 2012 (GLOBE NEWSWIRE) -- Oxygen Biotherapeutics, Inc. (Nasdaq:OXBT) and privately held Aurum Biosciences Ltd. of Glasgow, Scotland, today jointly announced they have signed...